By demonstrating the shortcomings of an actual model the modeler and readers are defining the value proposition of gathering additional data and further refinement of the model.
The converse can also happen, where further constraining the model via continual refinement can lead it to only work in narrow situations and break down substantially in a broader application.
An additional refinement is major analyst jockeys on these volatile growthies use a dividend discount model which gives weight to the negative impact of drug patent expirations 5 to 10 years out.